Sign in to view content

Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD

Neil M. Bressler, MD

Video
Published 2022

Related

Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) End of Study Results
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2020
Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD
Peter A. Campochiaro, MD
Annual Meeting Talks
2020
The Cilioretinal Artery is Protective Against Choroidal Neovascularization in Age-Related Macular Degeneration
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2018

Category: AMD-Neovascular

See more